{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '4.3', 'Immunogenicity', 'The following immunogenicity endpoint will be evaluated:', 'Impact of ADAs to OKZ on subject safety and efficacy', 'Amendment 2: 06 March 2019', '43', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '5. INVESTIGATIONAL PLAN', '5.1', 'Summary of Study Design', 'This is a multicenter, open-label, Phase III study that will evaluate the efficacy and safety of', 'OKZ in subjects with moderately to severely active RA who previously completed 24 weeks', 'of double-blind treatment in Study CL04041022, CL04041023, or CL04041025.', 'This study will be conducted at approximately 250 global sites across Russia, Belarus,', 'the US, Europe, the United Kingdom (UK), Asia, and Latin America. It is estimated that', 'approximately 1880 subjects will be enrolled.', 'Subjects will be assessed for eligibility to enter the study at Visit 1 (which is the same visit as', 'the Week 24 visit of the core studies), and eligible subjects will be assigned to 1 of 2 dosing', 'frequencies (q2w or q4w) of 64 mg OKZ as described in Section 5.2.', 'The study will consist of an 82-week open-label Treatment Period, with the last dose of OKZ', 'being administered at Week 104. After completion of the open-label Treatment Period,', 'subjects will come to Visit 10 (End of Treatment [EoT]/Week 106) 2 weeks after the last', 'dose of OKZ for scheduled safety and efficacy assessments. After Visit 10 (EoT/Week 106),', 'subjects will be scheduled for Safety Follow-Up Visits SFU-1 (Week 108), SFU-2', '(Week 112), and SFU-3 (Week 126) to perform adequate safety assessments.', 'The total amount of time to complete the OLE study will be approximately 102 weeks', '(inclusive of the open-label Treatment Period and the Safety Follow-Up Period). The total', 'amount of time to complete both the core study and the OLE study will be approximately', '130 weeks (2.5 years) (inclusive of the Screening, double-blind Treatment Period, open-label', 'Treatment Period, and Safety Follow-Up Period).', 'Subjects who discontinue treatment prematurely will be required to come to Visit 10', '(EoT/Week 106) 2 weeks after the last dose of study treatment for scheduled efficacy and', 'safety assessments. These subjects will subsequently be followed for an additional 20 weeks', '(i.e., 22 weeks after the final dose of study treatment) during a Safety Follow-Up Period.', 'A schematic of the study design is presented in Figure 1. The Schedule of Events to be', 'conducted during the 82-week open-label Treatment Period (Week 24 through Week 106)', 'and the Safety Follow-Up Period (Week 106 through Week 126) is presented in Table 1.', 'Amendment 2: 06 March 2019', '44', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Figure 1', 'CL04041024 (CREDO 4) Study Schematic', 'Double-blind', 'Treatment Period', 'Open-label Treatment Period', 'Safety Follow-Up Period', 'Weeks 0 to 24', 'Weeks 24 to 106', 'Weeks 106 to 126', 'I', 'I', 'Subjects who', 'have completed', 'OKZ 64 mg SC q4w + MTX', '24 weeks of', 'treatment in the', 'I', 'core studies', 'I', '(N=1880)', 'I', 'Enter Safety', 'I', 'R', 'Follow-Up', 'OKZ 64 mg SC q2w + MTX', 'I', 'I', 'I', 'Week 0', 'Week 24', 'Week 104', 'Week 106', 'Week 108', 'Week 112', 'Week 126', 'Core Baseline', 'OLE Baseline', 'Last Dose', 'EoT', 'Safety', 'Safety', 'Safety', 'Follow-Up', 'Follow-Up', 'Follow-Up', 'Abbreviations: EoT = End of Treatment; MTX = methotrexate; N = total number of subjects; OKZ = olokizumab; OLE = open-label extension; q2w = once', 'every 2 weeks; q4w = once every 4 weeks; R = randomization; SC = subcutaneous(ly).', 'Amendment 2: 06 March 2019', '45', 'Confidential']\n\n###\n\n", "completion": "END"}